{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:53:07Z","timestamp":1793137987959,"version":"4.5.0"},"reference-count":100,"publisher":"Japan Atherosclerosis Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2025,12,1]]},"DOI":"10.5551\/jat.rv22043","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T22:07:21Z","timestamp":1756505241000},"page":"1471-1481","source":"Crossref","is-referenced-by-count":9,"title":["Gout, Uric Acid, and Coronary Artery Disease"],"prefix":"10.5551","volume":"32","author":[{"given":"Takuya","family":"Nakahashi","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Takaoka City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Sakata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Takamura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Science"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Ahmad MI, Dutta A, Anees MA, Soliman EZ. Interrelations Between Serum Uric Acid, Silent Myocardial Infarction, and Mortality in the General Population. Am J Cardiol, 2019; 123: 882-888","DOI":"10.1016\/j.amjcard.2018.12.016"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Khan SW, Fayyaz A, Ullah I, Shahab M, Naeem K, Ahmad B, Shah SM. The Correlation of Serum Uric Acid Levels With the Severity of Coronary Artery Disease in Diabetic Patients: A Cross-Sectional Study. Cureus, 2023; 15(12):e50755","DOI":"10.7759\/cureus.50755"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Ndrepepa G, Kufner S, Cassese S, Joner M, Xhepa E, Wiebe J, Sager HB, Kessler T, Laugwitz KL, Schunkert H, Kastrati A. A Ten-Year Follow-Up Study of the Association Between Uric Acid and Adverse Cardiovascular Events in Patients With Coronary Artery Disease. Am J Cardiol, 2024; 216: 19-26","DOI":"10.1016\/j.amjcard.2024.01.024"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation, 2007; 116: 894-900","DOI":"10.1161\/CIRCULATIONAHA.107.703389"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Tamba S, Nishizawa H, Funahashi T, Okauchi Y, Ogawa T, Noguchi M, Fujita K, Ryo M, Kihara S, Iwahashi H, Yamagata K, Nakamura T, Shimomura I, Matsuzawa Y. Relationship between the serum uric acid level, visceral fat accumulation and serum adiponectin concentration in Japanese men. Intern Med, 2008; 47: 1175-1180","DOI":"10.2169\/internalmedicine.47.0603"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Ling Y, Tao Z, Wan Y, Cui H, Zhang Z, Pei J, Maimaiti A, Bai H, Wu Y, Li J, Zhao G, Zaid M. Associations of Sedentary Behavior with Risks of Cardiovascular Disease Events among Chinese Adults. J Atheroscler Thromb, 2024; 31: 1398-1415","DOI":"10.5551\/jat.64760"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Cui K, Song Y, Yin D, Song W, Wang H, Zhu C, Feng L, Fu R, Jia L, Lu Y, Zhang D, Song C, Yang Y, Dong Q, Dou K. Uric Acid Levels, Number of Standard Modifiable Cardiovascular Risk Factors, and Prognosis in Patients With Coronary Artery Disease: A Large Cohort Study in Asia. J Am Heart Assoc, 2023; 12: e030625","DOI":"10.1161\/JAHA.123.030625"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Palmer TM, Nordestgaard BG, Benn M, Tybj\u00e6rg-Hansen A, Davey Smith G, Lawlor DA, Timpson NJ. Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts. BMJ, 2013; 347: f4262","DOI":"10.1136\/bmj.f4262"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Keenan T, Zhao W, Rasheed A, Ho WK, Malik R, Felix JF, Young R, Shah N, Samuel M, Sheikh N, Mucksavage ML, Shah O, Li J, Morley M, Laser A, Mallick NH, Zaman KS, Ishaq M, Rasheed SZ, Memon FU, Ahmed F, Hanif B, Lakhani MS, Fahim M, Ishaq M, Shardha NK, Ahmed N, Mahmood K, Iqbal W, Akhtar S, Raheel R, O\u2019Donnell CJ, Hengstenberg C, M\u00e4rz W, Kathiresan S, Samani N, Goel A, Hopewell JC, Chambers J, Cheng YC, Sharma P, Yang Q, Rosand J, Boncoraglio GB, Kazmi SU, Hakonarson H, K\u00f6ttgen A, Kalogeropoulos A, Frossard P, Kamal A, Dichgans M, Cappola T, Reilly MP, Danesh J, Rader DJ, Voight BF, Saleheen D. Causal Assessment of Serum Urate Levels in Cardiometabolic Diseases Through a Mendelian Randomization Study. J Am Coll Cardiol, 2016; 67: 407-416","DOI":"10.1016\/j.jacc.2015.10.086"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Ndrepepa G. Uric acid and cardiovascular disease. Clin Chim Acta, 2018; 484: 150-163","DOI":"10.1016\/j.cca.2018.05.046"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Zhu J, Zeng Y, Zhang H, Qu Y, Ying Z, Sun Y, Hu Y, Chen W, Yang H, Yang J, Song H. The Association of Hyperuricemia and Gout With the Risk of Cardiovascular Diseases: A Cohort and Mendelian Randomization Study in UK Biobank. Front Med (Lausanne), 2022; 8: 817150","DOI":"10.3389\/fmed.2021.817150"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol, 2015; 11: 649-662","DOI":"10.1038\/nrrheum.2015.91"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Teramura S, Yamagishi K, Umesawa M, Hayama-Terada M, Muraki I, Maruyama K, Tanaka M, Kishida R, Kihara T, Takada M, Ohira T, Imano H, Shimizu Y, Sankai T, Okada T, Kitamura A, Kiyama M, Iso H. Risk Factors for Hyperuricemia or Gout in Men and Women: The Circulatory Risk in Communities Study (CIRCS). J Atheroscler Thromb, 2023; 30: 1483-1491","DOI":"10.5551\/jat.63907"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Rho YH, Lu N, Peloquin CE, Man A, Zhu Y, Zhang Y, Choi HK. Independent impact of gout on the risk of diabetes mellitus among women and men: a population-based, BMI-matched cohort study. Ann Rheum Dis, 2016; 75: 91-95","DOI":"10.1136\/annrheumdis-2014-205827"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med, 1999; 340: 115-126","DOI":"10.1056\/NEJM199901143400207"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Martinon F, P\u00e9trilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature, 2006; 440: 237-241","DOI":"10.1038\/nature04516"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ; CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med, 2017; 377: 1119-1131","DOI":"10.1056\/NEJMoa1707914"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Solomon DH, Glynn RJ, MacFadyen JG, Libby P, Thuren T, Everett BM, Ridker PM. Relationship of Interleukin-1\u03b2 Blockade With Incident Gout and Serum Uric Acid Levels: Exploratory Analysis of a Randomized Controlled Trial. Ann Intern Med, 2018; 169: 535-542","DOI":"10.7326\/M18-1167"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Cipolletta E, Tata LJ, Nakafero G, Avery AJ, Mamas MA, Abhishek A. Association Between Gout Flare and Subsequent Cardiovascular Events Among Patients With Gout. JAMA, 2022; 328: 440-450","DOI":"10.1001\/jama.2022.11390"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Clarson LE, Chandratre P, Hider SL, Belcher J, Heneghan C, Roddy E, Mallen CD. Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. Eur J Prev Cardiol, 2015; 22: 335-343","DOI":"10.1177\/2047487313514895"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Stamp LK, Frampton C, Drake J, Doughty RN, Troughton RW, Richards AM. Associations of Gout and Baseline Serum Urate Level With Cardiovascular Outcomes: Analysis of the Coronary Disease Cohort Study. Arthritis Rheumatol, 2019; 71: 1733-1738","DOI":"10.1002\/art.41007"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Jablonski K, Young NA, Henry C, Caution K, Kalyanasundaram A, Okafor I, Harb P, Schwarz E, Consiglio P, Cirimotich CM, Bratasz A, Sarkar A, Amer AO, Jarjour WN, Schlesinger N. Physical activity prevents acute inflammation in a gout model by downregulation of TLR2 on circulating neutrophils as well as inhibition of serum CXCL1 and is associated with decreased pain and inflammation in gout patients. PLoS One, 2020; 15: e0237520","DOI":"10.1371\/journal.pone.0237520"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Chen JH, Wen CP, Wu SB, Lan JL, Tsai MK, Tai YP, Lee JH, Hsu CC, Tsao CK, Wai JP, Chiang PH, Pan WH, Hsiung CA. Attenuating the mortality risk of high serum uric acid: the role of physical activity underused. Ann Rheum Dis, 2015; 74: 2034-2042","DOI":"10.1136\/annrheumdis-2014-205312"},{"key":"24","unstructured":"24) Kannel WB, Castelli WP, McNamara PM. The coronary profile: 12-year follow-up in the Framingham study. J Occup Med, 1967; 9: 611-619"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Li M, Hu X, Fan Y, Li K, Zhang X, Hou W, Tang Z. Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis. Sci Rep, 2016; 6: 19520","DOI":"10.1038\/srep19520"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Bickel C, Rupprecht HJ, Blankenberg S, Rippin G, Hafner G, Daunhauer A, Hofmann KP, Meyer J. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol, 2002; 89: 12-17","DOI":"10.1016\/S0002-9149(01)02155-5"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Matsumoto I, Moriya S, Kurozumi M, Namba T, Takagi Y. Relationship between serum uric acid levels and the incidence of cardiovascular events after percutaneous coronary intervention. J Cardiol, 2021; 78: 550-557","DOI":"10.1016\/j.jjcc.2021.08.005"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Saito Y, Kitahara H, Nakayama T, Fujimoto Y, Kobayashi Y. Relation of Elevated Serum Uric Acid Level to Endothelial Dysfunction in Patients with Acute Coronary Syndrome. J Atheroscler Thromb, 2019; 26: 362-367","DOI":"10.5551\/jat.45179"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Nakahashi T, Sakata K, Masuda J, Kumagai N, Higuma T, Ogimoto A, Tanigawa T, Hanada H, Nakamura M, Takamura M, Dohi K. Impact of hyperuricemia on coronary blood flow and in-hospital mortality in patients with acute myocardial infarction undergoing percutaneous coronary intervention. J Cardiol, 2022; 80: 268-274","DOI":"10.1016\/j.jjcc.2022.04.009"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Takeshita M, Tanaka A, Yoshida H, Nakamura I, Shibata Y, Hata S, Kushiyama A, Okutsu M, Ishizu T, Node K. Effect of the Xanthine Oxidase Inhibitor, Febuxostat, on WBC Count in Asymptomatic Hyperuricemia: Subanalysis of the Randomized PRIZE Study. J Atheroscler Thromb, 2024; 31: 864-875","DOI":"10.5551\/jat.64574"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Kawachi Y, Fujishima Y, Nishizawa H, Tanaka A, Yoshida H, Niwano S, Suzuki M, Shimomura I, Node K. Effect of the Xanthine Oxidase Inhibitor Febuxostat on the Cardio-Ankle Vascular Index in Asymptomatic Patients with Hyperuricemia and Liver Dysfunction: A Sub-Analysis of the PRIZE Study. J Atheroscler Thromb, 2025; 32: 474-490","DOI":"10.5551\/jat.65087"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Nakamura M, Ako J, Arai H, Hirayama A, Nohara A, Murakami Y, Ozaki A, Harada-Shiba M. Lipid Management and 2-Year Clinical Outcomes in Japanese Patients with Acute Coronary Syndrome: EXPLORE-J. J Atheroscler Thromb, 2021; 28: 1307-1322","DOI":"10.5551\/jat.59543"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Centola M, Maloberti A, Castini D, Persampieri S, Sabatelli L, Ferrante G, Lucreziotti S, Morici N, Sacco A, Oliva F, Rebora P, Giannattasio C, Mafrici A, Carugo S. Impact of admission serum acid uric levels on in-hospital outcomes in patients with acute coronary syndrome. Eur J Intern Med, 2020; 82: 62-67","DOI":"10.1016\/j.ejim.2020.07.013"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Liu W, Yu W, Xie D, Wang Q, Zhao H, Lv J, He F, Xu C, Chen B, Yamamoto T, Koyama H, Cheng J. High Uric Acid Promotes Atherosclerotic Plaque Instability by Apoptosis Targeted Autophagy. J Atheroscler Thromb, 2023; 30: 1176-1186","DOI":"10.5551\/jat.63645"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Saito Y, Nakayama T, Sugimoto K, Fujimoto Y, Kobayashi Y. Relation of Lipid Content of Coronary Plaque to Level of Serum Uric Acid. Am J Cardiol, 2015; 116: 1346-1350","DOI":"10.1016\/j.amjcard.2015.07.059"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Kobayashi N, Hata N, Tsurumi M, Shibata Y, Okazaki H, Shirakabe A, Takano M, Seino Y, Shimizu W. Relation of Coronary Culprit Lesion Morphology Determined by Optical Coherence Tomography and Cardiac Outcomes to Serum Uric Acid Levels in Patients With Acute Coronary Syndrome. Am J Cardiol, 2018; 122: 17-25","DOI":"10.1016\/j.amjcard.2018.03.022"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Zhang D, Zhang R, Wang N, Lin L, Yu B. Correlation of Serum Uric Acid Levels with Nonculprit Plaque Instability in Patients with Acute Coronary Syndromes: A 3-Vessel Optical Coherence Tomography Study. Biomed Res Int, 2018; 2018: 7919165","DOI":"10.1155\/2018\/7919165"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Mori N, Saito Y, Saito K, Matsuoka T, Tateishi K, Kadohira T, Kitahara H, Fujimoto Y, Kobayashi Y. Relation of Plasma Xanthine Oxidoreductase Activity to Coronary Lipid Core Plaques Assessed by Near-Infrared Spectroscopy Intravascular Ultrasound in Patients With Stable Coronary Artery Disease. Am J Cardiol, 2020; 125: 1006-1012","DOI":"10.1016\/j.amjcard.2019.12.043"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Abe M, Morimoto T, Morino Y, Tanaka H, Akao M, Hayashi Y, Muramatsu T, Ochiai M, Noguchi Y, Yumoto K, Shibata Y, Hiasa Y, Doi O, Yamashita T, Hinohara T, Kadota K, Kimura T; J-CTO Registry Investigators. Association between J-CTO score and long-term target lesion revascularization rate after successful chronic total coronary occlusion angioplasty (from the J-CTO Registry). Catheter Cardiovasc Interv, 2019; 93: 1025-1032","DOI":"10.1002\/ccd.28104"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Kang J, Cho YS, Kim SW, Park JJ, Yoon YE, Oh IY, Yoon CH, Suh JW, Youn TJ, Chae IH, Choi DJ. Intravascular Ultrasound and Angiographic Predictors of In-Stent Restenosis of Chronic Total Occlusion Lesions. PLoS One, 2015; 10: e0140421","DOI":"10.1371\/journal.pone.0140421"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol, 2005; 16: 3553-3362","DOI":"10.1681\/ASN.2005050572"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Turak O, Canpolat U, \u00d6zcan F, Mendi MA, Oks\u00fcz F, I\u015fleyen A, G\u00fcrel OM, \u00c7ay S, Aras D, Aydo\u011fdu S. Usefulness of preprocedural serum uric acid level to predict restenosis of bare metal stents. Am J Cardiol, 2014; 113: 197-202","DOI":"10.1016\/j.amjcard.2013.09.004"},{"key":"43","unstructured":"43) Wang JL, Qin Z, Wang ZJ, Shi DM, Liu YY, Zhao YX, Yang LX, Cheng WJ, Zhou YJ. New predictors of in-stent restenosis in patients with diabetes mellitus undergoing percutaneous coronary intervention with drug-eluting stent. J Geriatr Cardiol, 2018; 15: 137-145"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Joo HJ, Jeong HS, Kook H, Lee SH, Park JH, Hong SJ, Yu CW, Lim DS. Impact of hyperuricemia on clinical outcomes after percutaneous coronary intervention for in-stent restenosis. BMC Cardiovasc Disord, 2018; 18: 114","DOI":"10.1186\/s12872-018-0840-2"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Okuya Y, Saito Y, Takahashi T, Kishi K. Impact of Elevated Serum Uric Acid Level on Target Lesion Revascularization After Percutaneous Coronary Intervention for Chronic Total Occlusion. Am J Cardiol, 2019; 124: 1827-1832","DOI":"10.1016\/j.amjcard.2019.09.004"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Feng Q, Zhao Y, Wang H, Zhao J, Wang X, Shi J. A predictive model involving serum uric acid, C-reactive protein, diabetes, hypercholesteremia, multiple lesions for restenosis risk in everolimus-eluting stent-treated coronary heart disease patients. Front Cardiovasc Med, 2022; 9: 857922","DOI":"10.3389\/fcvm.2022.857922"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Nakahashi T, Tada H, Sakata K, Yakuta Y, Yoshida T, Tanaka Y, Nomura A, Terai H, Horita Y, Ikeda M, Namura M, Takamura M, Kawashiri MA. Impact of concomitant peripheral artery disease on contrast-induced acute kidney injury and mortality in patients with acute coronary syndrome after percutaneous coronary intervention. Heart Vessels, 2020; 35: 1360-1367","DOI":"10.1007\/s00380-020-01614-z"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Kanai D, Fujii H, Nakai K, Kono K, Watanabe K, Goto S, Nishi S. Statin Use Influence on the Occurrence of Acute Kidney Injury in Patients with Peripheral Arterial Disease. J Atheroscler Thromb, 2022; 29: 1646-1654","DOI":"10.5551\/jat.63265"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Zuo T, Jiang L, Mao S, Liu X, Yin X, Guo L. Hyperuricemia and contrast-induced acute kidney injury: A systematic review and meta-analysis. Int J Cardiol, 2016; 224: 286-294","DOI":"10.1016\/j.ijcard.2016.09.033"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Xu X, Hu J, Song N, Chen R, Zhang T, Ding X. Hyperuricemia increases the risk of acute kidney injury: a systematic review and meta-analysis. BMC Nephrol, 2017; 18: 27","DOI":"10.1186\/s12882-016-0433-1"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Pannu N, James M, Hemmelgarn BR, Dong J, Tonelli M, Klarenbach S; Alberta Kidney Disease Network. Modification of outcomes after acute kidney injury by the presence of CKD. Am J Kidney Dis, 2011; 58: 206-213","DOI":"10.1053\/j.ajkd.2011.01.028"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Feig DI. Uric acid: a novel mediator and marker of risk in chronic kidney disease? Curr Opin Nephrol Hypertens, 2009; 18: 526-530","DOI":"10.1097\/MNH.0b013e328330d9d0"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Park SH, Shin WY, Lee EY, Gil HW, Lee SW, Lee SJ, Jin DK, Hong SY. The impact of hyperuricemia on in-hospital mortality and incidence of acute kidney injury in patients undergoing percutaneous coronary intervention. Circ J, 2011 ;75: 692-697","DOI":"10.1253\/circj.CJ-10-0631"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). J Am Coll Cardiol, 2014; 63: 71-79","DOI":"10.1016\/j.jacc.2013.04.105"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Erol T, Tekin A, Kat\u0131rc\u0131ba\u015f\u0131 MT, Sezgin N, Bilgi M, Tekin G, Z\u00fcmr\u00fctdal A, Sezgin AT, M\u00fcderriso\u011flu H. Efficacy of allopurinol pretreatment for prevention of contrast-induced nephropathy: a randomized controlled trial. Int J Cardiol, 2013; 167: 1396-1399","DOI":"10.1016\/j.ijcard.2012.04.068"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Badreldin H, Mallya Prabhakar P. Evaluating the Role of Allopurinol in Mitigating Contrast-Induced Nephropathy in Percutaneous Coronary Intervention Patients: A Systematic Review and Meta-Analysis. Cureus, 2024; 16: e76374","DOI":"10.7759\/cureus.76374"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Hamaguchi S, Furumoto T, Tsuchihashi-Makaya M, Goto K, Goto D, Yokota T, Kinugawa S, Yokoshiki H, Takeshita A, Tsutsui H; JCARE-CARD Investigators. Hyperuricemia predicts adverse outcomes in patients with heart failure. Int J Cardiol, 2011; 151: 143-147","DOI":"10.1016\/j.ijcard.2010.05.002"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Fujihashi T, Sakata Y, Nochioka K, Miura M, Abe R, Kasahara S, Sato M, Aoyanagi H, Yamanaka S, Hayashi H, Shiroto T, Sugimura K, Takahashi J, Miyata S, Shimokawa H; CHART-2 Investigators. Prognostic impacts of serum uric acid levels in patients with chronic heart failure: insights from the CHART-2 study. ESC Heart Fail, 2021; 8: 1027-1038","DOI":"10.1002\/ehf2.12765"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Okazaki H, Shirakabe A, Kobayashi N, Hata N, Shinada T, Matsushita M, Yamamoto Y, Shibuya J, Shiomura R, Nishigoori S, Asai K, Shimizu W. The prognostic impact of uric acid in patients with severely decompensated acute heart failure. J Cardiol, 2016; 68: 384-391","DOI":"10.1016\/j.jjcc.2016.04.013"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Lim SS, Yang YL, Chen SC, Wu CH, Huang SS, Chan WL, Lin SJ, Chen JW, Chou CY, Pan JP, Charng MJ, Chen YH, Wu TC, Lu TM, Hsu PF, Huang PH, Cheng HM, Huang CC, Sung SH, Lin YJ, Leu HB. Association of variability in uric acid and future clinical outcomes of patient with coronary artery disease undergoing percutaneous coronary intervention. Atherosclerosis, 2020; 297: 40-46","DOI":"10.1016\/j.atherosclerosis.2020.01.025"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Akashi N, Kuwabara M, Matoba T, Kohro T, Oba Y, Kabutoya T, Imai Y, Kario K, Kiyosue A, Mizuno Y, Nochioka K, Nakayama M, Iwai T, Nakao Y, Iwanaga Y, Miyamoto Y, Ishii M, Nakamura T, Tsujita K, Sato H, Fujita H, Nagai R. Hyperuricemia predicts increased cardiovascular events in patients with chronic coronary syndrome after percutaneous coronary intervention: A nationwide cohort study from Japan. Front Cardiovasc Med, 2023; 9: 1062894","DOI":"10.3389\/fcvm.2022.1062894"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Nidorf SM, Fiolet A, Abela GS. Viewing atherosclerosis through a crystal lens: How the evolving structure of cholesterol crystals in atherosclerotic plaque alters its stability. J Clin Lipidol, 2020; 14: 619-630","DOI":"10.1016\/j.jacl.2020.07.003"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Yildiz A, Yilmaz R, Demirbag R, Gur M, Bas MM, Erel O. Association of serum uric acid level and coronary blood flow. Coron Artery Dis, 2007; 18: 607-613","DOI":"10.1097\/MCA.0b013e3282f0a2a7"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Uysal OK, Sahin DY, Duran M, Turkoglu C, Yildirim A, Elbasan Z, Ozkan B, Tekin K, Kunak AU, Yilmaz Y, Kaya MG, Gur M, Cayli M. Association between uric acid and coronary collateral circulation in patients with stable coronary artery disease. Angiology, 2014; 65: 227-231","DOI":"10.1177\/0003319713500706"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van\u2019 t Veer M, Klauss V, Manoharan G, Engstr\u00f8m T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF; FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med, 2009; 360: 213-224","DOI":"10.1056\/NEJMoa0807611"},{"key":"66","unstructured":"66) Topal S, Sezen\u00f6z B, Candemir M, A\u00e7ikg\u00f6z E, A\u00e7ikg\u00f6z SK, Boyaci NB. An old friend: uric acid and its association with fractional flow reserve. Turk J Med Sci, 2019; 49: 1614-1619"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67) Li F, Lin Q, Zhou J, Zhu J, Zhou Y, Wu K, Li Q, Zhao D, Liu Q. A high level of uric acid is associated with long-term adverse cardiovascular outcomes in patients who received fractional flow reserve with coronary intermediate stenosis. Nutr Metab Cardiovasc Dis, 2024; 34: 1538-1545","DOI":"10.1016\/j.numecd.2024.03.004"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68) Kunadian V, Chieffo A, Camici PG, Berry C, Escaned J, Maas AHEM, Prescott E, Karam N, Appelman Y, Fraccaro C, Louise Buchanan G, Manzo-Silberman S, Al-Lamee R, Regar E, Lansky A, Abbott JD, Badimon L, Duncker DJ, Mehran R, Capodanno D, Baumbach A. An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. Eur Heart J, 2020; 41: 3504-3520","DOI":"10.1093\/eurheartj\/ehaa503"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69) Bozcali E, Polat V, Aciksari G, Opan S, Bayrak IH, Paker N, Karakaya O. Serum concentrations of galectin-3 in patients with cardiac syndrome X. Atherosclerosis, 2014; 237: 259-263","DOI":"10.1016\/j.atherosclerosis.2014.09.014"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70) Saito Y, Kitahara H, Nishi T, Fujimoto Y, Kobayashi Y. Systemic endothelial dysfunction in patients with vasospastic and microvascular angina: serum uric acid as a marker of reactive hyperemia index. Coron Artery Dis, 2020; 31: 565-566","DOI":"10.1097\/MCA.0000000000000874"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71) Nishino M, Mori N, Yoshimura T, Nakamura D, Lee Y, Taniike M, Makino N, Kato H, Egami Y, Shutta R, Tanouchi J, Yamada Y. Higher serum uric acid and lipoprotein(a) are correlated with coronary spasm. Heart Vessels, 2014; 29: 186-190","DOI":"10.1007\/s00380-013-0346-x"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72) Tanazawa K, Akioka H, Yufu K, Makita T, Sato H, Iwabuchi Y, Ono Y, Yamasaki H, Takahashi M, Ogawa N, Harada T, Mitarai K, Kodama N, Yamauchi S, Takano M, Hirota K, Miyoshi M, Yonezu K, Tawara K, Abe I, Kondo H, Saito S, Fukui A, Fukuda T, Shinohara T, Akiyoshi K, Teshima Y, Takahashi N. Association between serum level of uric acid in Japanese young patients with coronary spastic angina receiving coronary angiography. Heart Vessels, 2025; 40: 295-301","DOI":"10.1007\/s00380-024-02469-4"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73) Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet, 2010; 375: 2161-2167","DOI":"10.1016\/S0140-6736(10)60391-1"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74) Tamariz L, Agarwal S, Soliman EZ, Chamberlain AM, Prineas R, Folsom AR, Ambrose M, Alonso A. Association of serum uric acid with incident atrial fibrillation (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol, 2011; 108: 1272-1276","DOI":"10.1016\/j.amjcard.2011.06.043"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75) Numa S, Hirai T, Nakagawa K, Ohara K, Fukuda N, Nozawa T, Inoue H. Hyperuricemia and transesophageal echocardiographic thromboembolic risk in patients with atrial fibrillation at clinically low-intermediate risk. Circ J, 2014; 78: 1600-1605","DOI":"10.1253\/circj.CJ-13-1385"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76) Tamariz L, Hernandez F, Bush A, Palacio A, Hare JM. Association between serum uric acid and atrial fibrillation: a systematic review and meta-analysis. Heart Rhythm, 2014; 11:1102-1108","DOI":"10.1016\/j.hrthm.2014.04.003"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77) Taufiq F, Maharani N, Li P, Kurata Y, Ikeda N, Kuwabara M, Otani N, Miake J, Hasegawa A, Tsuneto M, Shirayoshi Y, Ninomiya H, Saitoh T, Nakai A, Yamamoto K, Hisatome I. Uric Acid-Induced Enhancements of Kv1.5 Protein Expression and Channel Activity via the Akt-HSF1-Hsp70 Pathway in HL-1 Atrial Myocytes. Circ J, 2019; 83: 718-726","DOI":"10.1253\/circj.CJ-18-1088"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78) Maharani N, Kuwabara M, Hisatome I. Hyperuricemia and Atrial Fibrillation. Int Heart J, 2016; 57: 395-399","DOI":"10.1536\/ihj.16-192"},{"key":"79","unstructured":"79) Memetoglu ME, Kehlibar T, Y\u0131lmaz M, G\u00fcnay R, Arslan Y, Tuygun A, Kocaaslan C, \u00c7oskun G, Ketenci B, G\u00fcney MR, Demirtas M. Serum uric acid level predicts new-onset atrial fibrillation after coronary artery bypass graft operation. Eur Rev Med Pharmacol Sci, 2015; 19: 784-789"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80) Asada Y, Yamashita A, Sato Y, Hatakeyama K. Pathophysiology of atherothrombosis: Mechanisms of thrombus formation on disrupted atherosclerotic plaques. Pathol Int, 2020; 70: 309-322","DOI":"10.1111\/pin.12921"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81) Wang H, Jacobs DR Jr, Gaffo AL, Gross MD, Goff DC Jr, Carr JJ. Longitudinal association between serum urate and subclinical atherosclerosis: the Coronary Artery Risk Development in Young Adults (CARDIA) study. J Intern Med, 2013; 274: 594-609","DOI":"10.1111\/joim.12120"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82) Liang L, Hou X, Bainey KR, Zhang Y, Tymchak W, Qi Z, Li W, Banh HL. The association between hyperuricemia and coronary artery calcification development: A systematic review and meta-analysis. Clin Cardiol, 2019; 42: 1079-1086","DOI":"10.1002\/clc.23266"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83) Andr\u00e9s M, Quintanilla MA, Sivera F, S\u00e1nchez-Pay\u00e1 J, Pascual E, Vela P, Ruiz-Nodar JM. Silent Monosodium Urate Crystal Deposits Are Associated With Severe Coronary Calcification in Asymptomatic Hyperuricemia: An Exploratory Study. Arthritis Rheumatol, 2016; 68: 1531-1539","DOI":"10.1002\/art.39581"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84) Schwabl C, Taljanovic M, Widmann G, Teh J, Klauser AS. Ultrasonography and dual-energy computed tomography: impact for the detection of gouty deposits. Ultrasonography, 2021; 40: 197-206","DOI":"10.14366\/usg.20063"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85) Lee KA, Ryu SR, Park SJ, Kim HR, Lee SH. Assessment of cardiovascular risk profile based on measurement of tophus volume in patients with gout. Clin Rheumatol, 2018; 37: 1351-1358","DOI":"10.1007\/s10067-017-3963-4"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86) Patetsios P, Song M, Shutze WP, Pappas C, Rodino W, Ramirez JA, Panetta TF. Identification of uric acid and xanthine oxidase in atherosclerotic plaque. Am J Cardiol, 2001; 88: 188-191, A6","DOI":"10.1016\/S0002-9149(01)01621-6"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87) Held J, Schwabl C, Haschka D, Maier S, Feuchtner G, Widmann G, Duftner C, Weiss G, Klauser A. Major cardiovascular events in patients with cardiovascular monosodium urate deposits in atherosclerotic plaques. Rheumatology (Oxford), 2025; 64: 1443-1447","DOI":"10.1093\/rheumatology\/keae240"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88) Klauser AS, Halpern EJ, Strobl S, Gruber J, Feuchtner G, Bellmann-Weiler R, Weiss G, Stofferin H, Jaschke W. Dual-Energy Computed Tomography Detection of Cardiovascular Monosodium Urate Deposits in Patients With Gout. JAMA Cardiol, 2019; 4: 1019-1028","DOI":"10.1001\/jamacardio.2019.3201"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89) Nishimiya K, Sharma G, Singh K, Ahsen OO, Gardecki JA, Tearney GJ. Imaging human coronary cholesterol\/urate crystals with cross-polarized micro-optical coherence tomography. Front Cardiovasc Med, 2024; 11: 1433227","DOI":"10.3389\/fcvm.2024.1433227"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90) Kawabe M, Sato A, Hoshi T, Sakai S, Hiraya D, Watabe H, Kakefuda Y, Ishibashi M, Abe D, Takeyasu N, Aonuma K. Gender differences in the association between serum uric acid and prognosis in patients with acute coronary syndrome. J Cardiol, 2016; 67: 170-176","DOI":"10.1016\/j.jjcc.2015.05.009"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91) Yin Z, Fang Z, Yang M, Du X, Nie B, Gao K. Predictive value of serum uric acid levels on mortality in acute coronary syndrome patients with chronic kidney disease after drug-eluting stent implantation. Cardiology, 2013; 125: 204-212","DOI":"10.1159\/000350953"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92) Liu CW, Liao PC, Chen KC, Chiu YW, Liu YH, Ke SR, Wu YW. Relationship of serum uric acid and Killip class on mortality after acute ST-segment elevation myocardial infarction and primary percutaneous coronary intervention. Int J Cardiol, 2017; 226: 26-33","DOI":"10.1016\/j.ijcard.2016.10.025"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93) Nakahashi T, Tada H, Sakata K, Yoshida T, Tanaka Y, Nomura A, Terai H, Horita Y, Ikeda M, Namura M, Takamura M, Kawashiri MA. The Association Between Serum Uric Acid and Mortality in Patients with Acute Coronary Syndrome After Percutaneous Coronary Intervention. Int Heart J, 2022; 63: 447-453","DOI":"10.1536\/ihj.21-764"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94) Gwag HB, Yang JH, Park TK, Song YB, Hahn JY, Choi JH, Lee SH, Gwon HC, Choi SH. Uric Acid Level Has a U-shaped Association with Clinical Outcomes in Patients with Vasospastic Angina. J Korean Med Sci, 2017; 32: 1275-1280","DOI":"10.3346\/jkms.2017.32.8.1275"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95) Sugihara S, Hisatome I, Kuwabara M, Niwa K, Maharani N, Kato M, Ogino K, Hamada T, Ninomiya H, Higashi Y, Ichida K, Yamamoto K. Depletion of Uric Acid Due to SLC22A12 (URAT1) Loss-of-Function Mutation Causes Endothelial Dysfunction in Hypouricemia. Circ J, 2015; 79: 1125-1132","DOI":"10.1253\/circj.CJ-14-1267"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96) Kojima S, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Hiramitsu S, Waki M, Jinnouchi H, Kakuda H, Hayashi T, Kawai N, Sugawara M, Mori H, Tsujita K, Matsui K, Hisatome I, Ohya Y, Kimura K, Saito Y, Ogawa H; Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study (FREED) investigators. Optimal uric acid levels by febuxostat treatment and cerebral, cardiorenovascular risks: post hoc analysis of a randomized controlled trial. Rheumatology (Oxford), 2022; 61: 2346-2359","DOI":"10.1093\/rheumatology\/keab739"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97) White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L; CARES Investigators. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med, 2018; 378: 1200-1210","DOI":"10.1056\/NEJMoa1710895"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98) Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, Ralston SH, Walters M, Robertson M, De Caterina R, Findlay E, Perez-Ruiz F, McMurray JJV, MacDonald TM; FAST Study Group. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet, 2020; 396: 1745-1757","DOI":"10.1016\/S0140-6736(20)32234-0"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99) Kojima S, Matsui K, Hiramitsu S, Hisatome I, Waki M, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Jinnouchi H, Kakuda H, Hayashi T, Kawai N, Mori H, Sugawara M, Ohya Y, Kimura K, Saito Y, Ogawa H. Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy. Eur Heart J, 2019; 40: 1778-1786","DOI":"10.1093\/eurheartj\/ehz119"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100) Mackenzie IS, Hawkey CJ, Ford I, Greenlaw N, Pigazzani F, Rogers A, Struthers AD, Begg AG, Wei L, Avery AJ, Taggar JS, Walker A, Duce SL, Barr RJ, Dumbleton JS, Rooke ED, Townend JN, Ritchie LD, MacDonald TM; ALL-HEART Study Group. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet, 2022; 400: 1195-1205","DOI":"10.1016\/S0140-6736(22)01657-9"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/32\/12\/32_RV22043\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:20:57Z","timestamp":1764994857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/32\/12\/32_RV22043\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":100,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.rv22043","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"article-number":"RV22043"}}